Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company’s resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults.

View article:
FDA accepts Allergan’s resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Scroll to Top